GlassScriptPhysician profile
Stefani Beverlin
NPI 1497884134
$1,128.85
in general payments reported to CMS, 2019-2025
14 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.34 · 2022: $55.89 · 2023: $327 · 2024: $348 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $270.01 | 2023-2025 | Gemtesa, Myfembree |
| Astellas Pharma US INC | $202.85 | 2023-2025 | Veozah |
| Amgen INC. | $132.86 | 2024 | Evenity, Prolia |
| Abbvie INC. | $111.45 | 2023 | |
| Myovant Sciences INC. | $105.22 | 2021-2022 | |
| Sage Therapeutics, LLC | $94.25 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $47.51 | 2023-2025 | |
| Exeltis, USA INC. | $43.02 | 2023-2025 | Slynd |
| Hologic Sales and Service, LLC | $30.03 | 2021-2022 | |
| Minerva Surgical, INC | $19.98 | 2022 | |
| Supernus Pharmaceuticals, INC. | $19.70 | 2025 | Qelbree |
| Organon LLC | $18.99 | 2025 | Nexplanon |
| Lilly USA, LLC | $16.78 | 2025 | Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $16.20 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefani Beverlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.